Blog

World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19

The World Health Organization (WHO) has placed baricitinib, an approved rheumatoid arthritis drug first identified as a treatment by BenevolentAI, at the top of its live guideline of drugs to treat COVID-19.

On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. 

BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint baricitinib by using computational tools to augment scientific expertise and enable scientists to extract new insights from existing data. The work began by enhancing BenevolentAI’s biomedical knowledge graph — which includes public and licensed data from scientific literature, patents, genetics, chemistry, clinical trials and BenevolentAI’s proprietary data — with SARS-CoV-2 (or nCoV as it was known then) specific information using AI.

BenevolentAI retrieved 40,000 novel relationships from the data in the graph for its AI and machine learning (ML) tools to create mechanistic networks. BenevolentAI scientists then supplemented this with relevant biological context so that the network represented, at a molecular level, how SARS-CoV-2 enters and infects cells, as well as the potentially lethal inflammatory response, the so-called ‘cytokine storm’. Focusing on these aspects, the scientific team short-listed 40 drugs, finally identifying the Janus kinase (JAK) inhibitor baricitinib as the strongest candidate. They based the decision on its ability to inhibit both virus entry into cells and the “cytokine storm” responsible for much of the COVID-19 induced mortality. The whole process took just two days. 

BenevolentAI’s team informed baricitinib’s owner, Eli Lilly, of its previously unknown antiviral properties. Subsequent observational tests of baricitinib in patients in the EU spurred the National Institute of Allergy and Infectious Diseases (NIAID) and Eli Lilly to conduct randomised clinical trials. Data from the first randomised clinical trial (ACTT-2) prompted the FDA to issue an Emergency Use Authorization for baricitinib in hospitalised COVID-19 patients in November 2020. Further analysis of the data from the second randomised clinical trial (COV-BARRIER) showed that the risk of dying from severe disease was reduced by 38%, an effect much greater than that seen with all other therapies. 

In response to the updated WHO guidelines, Professor Vincent Marconi — Professor of Medicine and Global Health at the Emory School of Medicine and leader of the COV-BARRIER trial — commented: “The WHO guidelines reflect the best available evidence, derived from properly conducted multi-centre randomised-controlled phase 3 studies. As baricitinib is oral, inexpensive, has dose flexibility, a short half-life and lacks drug-drug interactions, it has also been made freely available upon request for low and middle income countries where access to vaccines and appropriate therapies has been difficult."  

The WHO guidelines, published in the British Medical Journal, is a living document that has just been updated based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.

More Posts

You Might Also Like

News
BenevolentAI Appoints Daniel Neil as Chief Technology Officer
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Jan 21, 2022
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
BenevolentAI and AstraZeneca add systemic lupus erythematosus and heart failure to their expanded AI drug discovery collaboration.
Jan 13, 2022
News
BenevolentAI to Present at the 40th Annual JP Morgan Healthcare Conference
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 6, 2022
Blog
It’s up to us: reflections on responsible innovation
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.
Dec 22, 2021
News
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca’s portfolio
Novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s AI-driven drug discovery platform, selected to enter AstraZeneca’s portfolio.
Dec 15, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021